Media coverage about Synergy Pharmaceuticals (NASDAQ:SGYP) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.3081754784943 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s analysis:
Synergy Pharmaceuticals (NASDAQ:SGYP) traded down $0.26 during midday trading on Friday, reaching $2.18. 14,396,530 shares of the company traded hands, compared to its average volume of 5,789,718. Synergy Pharmaceuticals has a 52-week low of $1.68 and a 52-week high of $7.15. The company has a debt-to-equity ratio of -68.13, a current ratio of 4.26 and a quick ratio of 3.88. The stock has a market capitalization of $537.72, a price-to-earnings ratio of -1.88 and a beta of 1,040.57.
Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.06. The firm had revenue of $5.01 million for the quarter, compared to analysts’ expectations of $4.53 million. During the same quarter in the prior year, the business earned ($0.22) EPS. sell-side analysts anticipate that Synergy Pharmaceuticals will post -1.04 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $10.00 target price on shares of Synergy Pharmaceuticals in a research report on Tuesday, November 21st. Citigroup cut shares of Synergy Pharmaceuticals to a “market perform” rating in a research report on Friday. CIBC reissued a “market perform” rating on shares of Synergy Pharmaceuticals in a research report on Friday. Oppenheimer restated a “market perform” rating and issued a $10.00 price target on shares of Synergy Pharmaceuticals in a report on Friday. Finally, Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $8.38.
In other news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of Synergy Pharmaceuticals stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $2.82, for a total transaction of $24,675,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 3.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Synergy Pharmaceuticals (SGYP) Given Media Sentiment Score of 0.08” was originally posted by Equities Focus and is the sole property of of Equities Focus. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.equitiesfocus.com/2018/01/07/synergy-pharmaceuticals-sgyp-given-media-sentiment-score-of-0-08.html.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.